Search
tralokinumab-ldrm (Adbry, Adtralza)
Indications:
- treatment of atopic dermatitis
- may be used with or without topical glucocorticoids
Dosage:
- initial dose of 600 mg SQ (4 150 mg injections)
- follow with 300 mg (2 150 mg injections) SQ every other week.
- 300 mg every 4 weeks may be considered for patients below 100 kg who achieve clear or almost clear skin after 16 weeks of treatment
* 1 mL 50 mg/mL prefilled syringe
* 2 mL tralokinumab-ldrm 150 mg/mL auto-injector for subcutaneous injection
Adverse effects:
- hypersensitivity reactions
- keratitis & conjunctivitis
- eosinophilia & helminth infections
Mechanism of action:
- human IgG4 monoclonal antibody that specifically binds to human interleukin-13 (IL-13)
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
dermatologic agent
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Adbry (tralokinumab-ldrm) injection, for subcutaneous use
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761180s006lbl.pdf